TScan Therapeutics, Inc. — Director's Dealing 2021

Jul 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-07-15

Reporting Person: Silver Brian M. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-20	Voting Common Stock	P	1000	$15.00	Acquired	1000	Direct

Footnotes

F1: Represents shares purchased in the Issuer's initial public offering.